Faldaprevir
Faldaprevir
Faldaprevir (pronounced: fal-da-pre-vir) is an experimental antiviral drug for the treatment of Hepatitis C. It is a protease inhibitor, specifically targeting Hepatitis C virus NS3/4A serine protease.
Etymology
The name "Faldaprevir" is derived from the pharmaceutical naming conventions. The suffix "-previr" is used for agents affecting viral replication, indicating its use in the treatment of viral infections.
Mechanism of Action
Faldaprevir works by inhibiting the Hepatitis C virus NS3/4A serine protease, an enzyme that the virus uses to cleave and process the viral polyprotein, a critical step in the life cycle of the virus. By inhibiting this enzyme, Faldaprevir prevents the virus from replicating and spreading.
Clinical Trials
Faldaprevir has undergone Phase III clinical trials for the treatment of Hepatitis C. The drug has shown promise in these trials, with a high percentage of patients achieving a sustained virologic response.
Side Effects
Common side effects of Faldaprevir include fatigue, headache, nausea, and skin rash. More serious side effects can include liver damage and severe skin reactions.
Related Terms
External links
- Medical encyclopedia article on Faldaprevir
- Wikipedia's article - Faldaprevir
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski